Form 4 for VIR Vir Biotechnology, Inc.
Accepted 2021-09-24 00:00:00 ET · period of report 2021-09-22 · accession 0001209191-21-057641 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-09-24 | 2021-09-22 | VIR | Virgin Herbert | EVP, CSO, Research | M - OptEx | $1.53 | +8,000 | 107.7K | +8% | +$12.2K |
| D | 2021-09-24 | 2021-09-22 | VIR | Virgin Herbert | EVP, CSO, Research | M - OptEx | $0.00 | -8,000 | 251.1K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-09-22 | M | A | 8,000 | $1.53 | 107,700 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2021-09-22 | M | D | 8,000 | $0.00 | 251,130 | D | $1.53 · — to 2028-01-26 | 8,000 Common Stock | (F1) 1/4 of the shares subject to the stock option vested and became exercisable on January 8, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. |